Dermata TherapeuticsDRMA
Market Cap: $2.61M
About: Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
Employees: 8
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
163% more capital invested
Capital invested by funds: $29.8K [Q1] → $78.3K (+$48.4K) [Q2]
6.32% more ownership
Funds ownership: 1.13% [Q1] → 7.45% (+6.32%) [Q2]
14% less funds holding
Funds holding: 7 [Q1] → 6 (-1) [Q2]
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Maxim Group Anthony Vendetti 55% 1-year accuracy 6 / 11 met price target | 203%upside $6 | Buy Maintained | 21 Aug 2024 |
Financial journalist opinion
Based on 3 articles about DRMA published over the past 30 days